This study aims to fill this gap by investigating the predictive value of a single time point pre-therapeutic [68Ga]Ga-PSMA-PET for absorbed dose after [177Lu]Lu-PSMA therapy in organs (kidneys, salivary glands, and liver) and tumor lesions. This evidence concerns the gene FOLH1 and neoplasm.